Scientists discover a new brake on cell death

The protein ATG9A blocks the cell-killing signal of tumor necrosis factor and prevents unwanted cell death

Many inflammatory diseases develop when the body goes overboard and kills too many healthy cells. The group of Prof. Mathieu JM Bertrand (VIB-UGent Center for Inflammation Research), in collaboration with the team of Prof. Geert van Loo (VIB-UGent Center for Inflammation Research) and colleagues from the University of Regensburg and Juntendo University, has identified a new mechanism, mediated by the autophagy protein ATG9A, that blocks this excessive cell death. Their work appears in Science. 

Life or death 

Cell death can be good or bad. During infections, for example, our body can kill infected cells to safeguard healthy cells and stop the infection from spreading. However, the extent of cell death needs to be contained. Excessive cell death can be very harmful and lead to the development of many diseases, such as neurodegenerative disorders or autoimmune conditions. 

One of the key molecules involved in cell death is TNF, or Tumor Necrosis Factor, which can instruct the cell to kill itself. Normally, this lethal signal is suppressed by intracellular cell death checkpoints, which act as brakes on TNF’s killing potential. Yet, occasionally, TNF can still trigger death even when these brakes are active, indicating the existence of additional unknown cell death checkpoints. ​ 

Prof. Mathieu Bertrand: The cell death checkpoints that actively repress TNF cytotoxicity constitute crucial safeguards against various inflammatory diseases. Preliminary results from the lab indicated the existence of yet-to-be-discovered additional protective brakes in the TNF pathway.” 

Finding a new brake 

The team of Prof. Mathieu Bertrand, in collaboration with the group of Prof. Geert van Loo (VIB-UGent Center for Inflammation Research) and colleagues at the University of Regensburg and Juntendo University, identified such a new brake on TNF cytotoxicity. The lab discovered this new pro-survival mechanism by performing a CRISPR/Cas9 screen in mouse embryonic cells. This screen allowed the researchers to delete every gene in the genome and observe the effects of that deletion on TNF-induced killing. 

They found that a deletion of the gene coding for a protein known as ATG9A switched TNF to 'killing mode'. Further research revealed that ATG9A collaborates with a defined subset of ATG proteins to target toxic molecules activated by TNF for disassembly by the lysosomes, the cell's waste disposal system. When ATG9A (or any other component of the cell death brake) is absent, these pro-death molecules do not get removed, leading to unwanted cell death. ​ 

In addition, the researchers also demonstrated the physiological importance of this new cell death checkpoint using different mouse models. Removing the Atg9a gene in mice led to premature death, which was fully caused by excessive TNF-mediated cell death. Blocking this undesired cell death completely prevented the early lethality of these mice, highlighting the vital importance of this new cell death brake during development. Finally, the lab also found that this new cell death brake was crucial to prevent inflammatory skin disease in the mouse, which can potentially lead to the discovery of new treatments for people suffering from skin disorders. ​ 

Prof. Mathieu Bertrand: “While our results demonstrate the importance of this checkpoint to protect against TNF cytotoxicity in the mouse, it will now be interesting to look for mutations in ATG9A or other ATG components of the newly identified checkpoint in patients with inflammatory pathologies. Anti-TNF biologics would represent promising therapies for the patients carrying such mutations.” ​ 
Jon Huyghe, Mathieu Bertrand, and Dario Priem.

Publication 

ATG9A prevents TNF cytotoxicity by an unconventional lysosomal targeting pathway. Huyghe, Priem, et al. Science, 2022. 


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

 

 

Share

Latest stories

Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be
Website preview
Brain immune cells may help build Alzheimer’s plaques
A new study led by researchers from VIB and KU Leuven shows that immune cells called microglia can actively promote the formation of plaques in Alzheimer’s disease, challenging the long-standing view that these cells serve only as defenders against plaque buildup. The findings were recently published in PNAS.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be